Meta AnalysisID 2399
表没食子儿茶素没食子酸酯纳米颗粒对大鼠阿尔茨海默病体内治疗的有效性
CRD42022333012
What is the effectiveness of Epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer's disease? Context and rationale Alzheimer's disease (AD) is a neurodegenerative disorder and the most common form
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2399
- Evidence Id
- 10957
- Core Evidence Id
- 10957
- Source Meta Analysis Id
- 2350
- Herb2 Meta Analysis Id
- HBMA002350
- Crd Id
- CRD42022333012
- Title
- Effectiveness of Epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer's disease in rats
- Review Question
- What is the effectiveness of Epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer's disease? Context and rationale Alzheimer's disease (AD) is a neurodegenerative disorder and the most common form of dementia characterized by cognitive and memory impairment. AD is currently incurable and there is an urgent need to develop new cure. Epigallocatechin-3-gallate (EGCG) is a natural polyphenol found in solid green tea extract, and has been shown to possess potent metal chelation, antioxidant properties and protective effects against neuronal damage and brain edema. Different studies have addressed the potential neuroprotective effect of Epigallocatechin-3-O-gallate (EGCG) nanoparticles on animal models of AD. The precise understanding of the pathophysiology of Alzheimer's disease is essential for developing disease-modifying strategies able to halt their progression. Different animal models reproduce different aspects of the disease as behavioural and histopathological changes, as well as the molecular mechanisms underlying the disease. Thus, representing an important tool to better understand Alzheimer's disease pathophysiology and, hence, to establish new therapeutic strategies. Therefore, the results of this systematic review can be extrapolated to future clinical research due to the similarities between animals and humans. The purpose of this review is to analyze and summarize the in vivo pre-clinical studies on the use of EGCG in the prevention and the treatment of AD.
- Study Type Included
- Inclusion criteria: In vivo experimental animal models. controlled studies with a separate control group. Exclusion criteria: Clinical studies case report case study studies without a separate control group clinical trials. Studies will also be excluded if they are irrelevant to the association between Epigallocatechin gallate nanoparticles and Alzheimer disease .
- Condition Being Studied
- Participant
- Animal
- Inclusion criteria: Studies that investigated the protective effect of Epigallocatechin gallate nanoparticles on Alziehimer disease using: animal models ( mice or rat) Exclusion criteria: We will exclude studies which not conducted on mice or rats.
- Human Disease Modelled
- Alzheimer's disease
- Intervention
- Inclusion criteria: We will consider studies on Epigallocatechin gallate nanoparticles for Alzheimer's disease models. No restriction was applied for intervention. Exclusion criteria: Studies were excluded for the following reasons: (i) use of free Epigallocatechin gallate only, (ii) use of Epigallocatechin gallate nanoparticle associated with other compounds.
- Comparator Control
- Inclusion criteria: We will consider studies which evaluated the effectiveness of Epigallocatechin gallate nanoparticles compared with free Epigallocatechin gallate and/or negative control. Exclusion criteria: We will exclude studies that did not evaluate the effectiveness of Epigallocatechin gallate nanoparticles compared with free Epigallocatechin gallate and/or negative control.
- Main Outcome
- Outcome Measure
- Inclusion criteria: Studies that have information about the effectiveness of Epigallocatechin gallate nanoparticles on Alzheimer's disease such as anti-oxidation, anti-inflammation, anti-apoptosis, regulation of α-, β-, γ-secretase activity, inhibition of hyperphosphorylation of tau and/or reduction of AchE activity (continous data) Exclusion criteria: Outcomes are other than the effectiveness of Epigallocatechin gallate nanoparticles on Alzheimer's disease treatment.
- Additional Outcome
- Study Method
- Keyword
- Alzheimer Disease; Animals; Catechin; Humans; Nanoparticles; Rats; epigallocatechin gallate
- Contact
- Maha Khalifa [email protected]
- Organisational Affiliation
- AlAzhar university
- Funding Source
- no funding Grant number(s) No grant
- Other Selection Criteria
- Inclusion criteria (1) all eligible studies in the review Exclusion criteria: (1) Studies with full paper copy not available (2) duplicate studies found in more than one database and non-laboratory studies. (3) reviews, letters, personal opinions, book chapters, and conference abstracts
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Experimental animal exposure review
- Language
- English
- Country
- Egypt
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-05-17
- Registration Date
- 2022-07-26
- Anticipated Start Date
- 2022-05-17
- Anticipated Completion Date
- 2023-03-15
- Title Cn
- 表没食子儿茶素没食子酸酯纳米颗粒对大鼠阿尔茨海默病体内治疗的有效性
- Title En
- Effectiveness of Epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer's disease in rats
- Bilingual Status
- complete